Natco Pharma Limited — Updates, 08-04-2025: Press Release

NATCO Pharma Limited has provided a legal update regarding its planned launch of the generic version of Risdiplam in India. The Delhi High Court recently denied Roche’s request for an injunction against NATCO, although Roche has appealed this decision. The appellate bench has instructed both parties to maintain the status quo while the appeal is pending. NATCO has expressed its intent to launch Risdiplam only after securing clarity from the court, which is anticipated soon. The company plans to price the product at INR 15,900, with discounts available through a patient access program for qualifying patients. This development highlights NATCO's commitment to bringing affordable medication to the market while navigating legal challenges. Investors should watch closely as the situation unfolds, given its potential impact on revenue and market positioning in oncology.